102 related articles for article (PubMed ID: 23257765)
1. A and B blood group antigens in human pancreatic ductal adenocarcinomas.
Handra-Luca A
Oncology; 2013; 84(3):141-9. PubMed ID: 23257765
[TBL] [Abstract][Full Text] [Related]
2. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease.
Pai RK; Beck AH; Mitchem J; Linehan DC; Chang DT; Norton JA; Pai RK
Am J Surg Pathol; 2011 Feb; 35(2):228-34. PubMed ID: 21263243
[TBL] [Abstract][Full Text] [Related]
3. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
4. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
[TBL] [Abstract][Full Text] [Related]
5. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
6. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
Robinson SM; Rahman A; Haugk B; French JJ; Manas DM; Jaques BC; Charnley RM; White SA
Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
8. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic resection for M1 pancreatic ductal adenocarcinoma.
Shrikhande SV; Kleeff J; Reiser C; Weitz J; Hinz U; Esposito I; Schmidt J; Friess H; Büchler MW
Ann Surg Oncol; 2007 Jan; 14(1):118-27. PubMed ID: 17066229
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
[TBL] [Abstract][Full Text] [Related]
11. Improving survival following surgery for pancreatic ductal adenocarcinoma--a ten-year experience.
Hoem D; Viste A
Eur J Surg Oncol; 2012 Mar; 38(3):245-51. PubMed ID: 22217907
[TBL] [Abstract][Full Text] [Related]
12. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
[TBL] [Abstract][Full Text] [Related]
13. Low expression of junctional adhesion molecule A is associated with metastasis and poor survival in pancreatic cancer.
Fong D; Spizzo G; Mitterer M; Seeber A; Steurer M; Gastl G; Brosch I; Moser P
Ann Surg Oncol; 2012 Dec; 19(13):4330-6. PubMed ID: 22549289
[TBL] [Abstract][Full Text] [Related]
14. Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines.
Motoi F; Rikiyama T; Katayose Y; Egawa S; Unno M
Ann Surg Oncol; 2011 Feb; 18(2):371-9. PubMed ID: 20842460
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.
Waraya M; Yamashita K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Watanabe M
Ann Surg Oncol; 2009 May; 16(5):1231-40. PubMed ID: 19263172
[TBL] [Abstract][Full Text] [Related]
16. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
[TBL] [Abstract][Full Text] [Related]
17. Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer.
Matsumoto G; Muta M; Tsuruta K; Horiguchi S; Karasawa K; Okamoto A
Pancreatology; 2007; 7(2-3):167-73. PubMed ID: 17592230
[TBL] [Abstract][Full Text] [Related]
18. Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer.
Helm J; Centeno BA; Coppola D; Melis M; Lloyd M; Park JY; Chen DT; Malafa MP
Cancer; 2009 Sep; 115(18):4080-9. PubMed ID: 19626671
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.
Lenz J; Karasek P; Jarkovsky J; Muckova K; Dite P; Kala Z; Veselska R; Hermanova M
J Gastrointestin Liver Dis; 2011 Dec; 20(4):389-96. PubMed ID: 22187705
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
